US 12,441,744 B2
2,6,9-trisubstituted purines
Bernard Barlaam, Cambridge (GB); Michael Bodnarchuk, Cambridge (GB); Avipsa Ghosh, Waltham, MA (US); Frederick Goldberg, Cambridge (GB); Sudhir Hande, Waltham, MA (US); Phillip Lichtor, Waltham, MA (US); Kun Song, Waltham, MA (US); Qibin Su, Waltham, MA (US); Reem Telmesani, Waltham, MA (US); and James Sheppeck, Waltham, MA (US)
Assigned to ASTRAZENECA AB
Filed by ASTRAZENECA AB, Södertälje (SE)
Filed on Jan. 27, 2025, as Appl. No. 19/038,077.
Application 19/038,077 is a continuation of application No. 18/541,006, filed on Dec. 15, 2023.
Claims priority of provisional application 63/387,734, filed on Dec. 16, 2022.
Prior Publication US 2025/0197425 A1, Jun. 19, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 519/00 (2006.01); A61K 31/52 (2006.01); A61P 31/00 (2006.01); C07D 487/04 (2006.01)
CPC C07D 519/00 (2013.01) [A61K 31/52 (2013.01); A61P 31/00 (2018.01); C07D 487/04 (2013.01)] 19 Claims
 
1. A compound that is N-ethyl-3-((9-ethyl-2-((2-hydroxypentan-3-yl)-amino)-9H-purin-6-yl)amino) pyrrolidine-1-sulfonamide having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.